Clinical Trial

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

Study acronym: CHEERS
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of NRT6003 Injection compared to cTACE in patients with unresectable HCC.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-21; most recent amendment 2026-06-08.
Status change: Recruiting → Active, Not Recruiting 2026-06-08
Status change: Not Yet Recruiting → Recruiting 2025-04-20
Trial Details
NCT Number NCT06900543
Lead Sponsor Chengdu New Radiomedicine Technology Co. LTD.
Conditions Unresectable Hepatocellular Carcinoma
Enrollment 108 participants
Start Date 2025-04-15
Primary Completion 2027-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-09